Viking Therapeutics Inc’s recent filing unveils that its Chief Financial Officer ZANTE GREG unloaded Company’s shares for reported $1.9 million on Jan 05 ’26. In the deal valued at $32.90 per share,57,661 shares were sold. As a result of this transaction, ZANTE GREG now holds 189,891 shares worth roughly $6.03 million.
Then, Mancini Marianna sold 57,661 shares, generating $1,901,405 in total proceeds. Upon selling the shares at $32.98, the Chief Operating Officer now owns 409,190 shares.
Before that, Lian Brian sold 233,409 shares. Viking Therapeutics Inc shares valued at $7,692,121 were divested by the President & CEO at a price of $32.96 per share. As a result of the transaction, Lian Brian now holds 2,499,291 shares, worth roughly $79.38 million.
Canaccord Genuity initiated its Viking Therapeutics Inc [VKTX] rating to a Buy in a research note published on October 29, 2025; the price target was $106. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Goldman began covering VKTX with “Neutral” recommendation on April 08, 2025. Scotiabank started covering the stock on February 13, 2025. It rated VKTX as “a Sector outperform”.
Price Performance Review of VKTX
On Monday, Viking Therapeutics Inc [NASDAQ:VKTX] saw its stock fall -0.72% to $31.76. Over the last five days, the stock has lost -1.18%. Viking Therapeutics Inc shares have fallen nearly -21.77% since the year began. Nevertheless, the stocks have fallen -9.72% over the past one year.
How much short interest is there in Viking Therapeutics Inc?
A steep rise in short interest was recorded in Viking Therapeutics Inc stocks on 2025-12-31, growing by 1.35 million shares to a total of 24.34 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 22.99 million shares. There was a rise of 5.56%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 07, 2025 when Citigroup began covering the stock and recommended ‘”a Neutral”‘ rating along with a $38 price target.
